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Alternative splicing is a vast source of biological
regulation and diversity that is misregulated in can-
cer and other diseases. To investigate global control
of alternative splicing in human cells, we analyzed
splicing of mRNAs encoding Bcl2 family apoptosis
factors in a genome-wide siRNA screen. The screen
identifiedmany regulators ofBcl-x andMcl1 splicing,
notably an extensive network of cell-cycle factors
linked to aurora kinase A. Drugs or siRNAs that
induce mitotic arrest promote proapoptotic splicing
of Bcl-x, Mcl1, and caspase-9 and alter splicing of
other apoptotic transcripts. This response precedes
mitotic arrest, indicating coordinated upregulation
of prodeath splice variants that promotes apoptosis
in arrested cells. These shifts correspond to post-
translational turnover of splicing regulator ASF/SF2,
which directly binds and regulates these target
mRNAs and globally regulates apoptosis. Broadly,
our results reveal an alternative splicing network
linking cell-cycle control to apoptosis.INTRODUCTION
Nearly all human precursor messenger RNAs (pre-mRNAs)
undergo alternative splicing (AS), with tremendous variation
and specificity across tissues, development, and disease (Pan
et al., 2008). This vast complexity is a formidable challenge to
experimental and informatic analysis of AS and its physiological
roles (Blencowe, 2006). One emergent concept is that function-
ally coherent transcript populations, termed RNA ‘‘regulons,’’
are coregulated by dedicated RNA-binding proteins (RBPs) to
promote specific biological functions (Keene, 2007). These
RBPs, notably SR proteins and hnRNPs, ‘‘decode’’ transcript
cis elements and control stepwise assembly of spliceosomal
snRNPs: U1 at the 50 splice -site (ss), then U2 near the 30 ss,
and finally U5/4/6 (Wahl et al., 2009; Black, 2003). Splicing
control is integrated with signal transduction pathways, pro-
moting dynamic, context-driven regulation. Collectively, these
features produce robust cell- and tissue-specific signatures ofexon use that shape many aspects of cell fate (Moore and Silver,
2008). Exon signatures are radically transformed in tumors, but
the causes and consequences are unknown.
In this study, we examine AS of Bcl2 family apoptosis regula-
tors Bcl-x and Mcl1. Bcl2-like proteins contain up to four Bcl2-
homology (BH) domains (BH1–4) (Hardwick and Youle, 2009).
Factors possessing all four BH domains, including Bcl2, Bcl-xL,
and Mcl1L, antagonize apoptosis by preventing mitochondrial
outer membrane permeablization (MOMP), thus sequestering
proapoptotic factors in mitochondria. Factors lacking one or
more BH domain, including Bid, BAD, and BAX, are proapoptotic
and promote MOMP. A finely tuned balance of pro- and antia-
poptotic Bcl2-like factors therefore controls mitochondrial integ-
rity and hence downstream steps in apoptosis such as apopto-
some formation and caspase activation (Wang and Youle, 2009).
Remarkably,Bcl-x,Mcl1, and some otherBcl2 familymRNAs are
alternatively spliced to yield both long (L) antiapoptotic and short
(S) proapoptotic forms. For Bcl-x, use of an alternative 50 ss in
exon 2 excludes the BH1 and BH2 domains (Akgul et al.,
2004). For Mcl1, exon 2 skipping excludes the BH1 and BH2
domains and eliminates the downstream transmembrane
domain via frame shift.
Many cis-regulatory elements and trans-acting factors exert
combinatorial control of Bcl-x splicing. Most known regulators,
including Sam68, ASF/SF2, hnRNP F/H, SRp30c, and RBM25,
altered Bcl-x AS in vitro or when overexpressed in cell culture
(Cloutier et al., 2008; Zhou et al., 2008; Paronetto et al., 2007;
Garneau et al., 2005). In addition, in RNA interference (RNAi)-
based loss-of-function assays, depletion of Sam68 and
hnRNPA1 favored Bcl-xL formation, while depletion of U2
snRNP component SF3B1/SAP155 favored Bcl-xS (Paronetto
et al., 2007; Massiello et al., 2006). Comparably little is known
of Mcl1 splicing regulation.
Beyond Bcl2-like factors, caspases, ‘‘death receptors,’’
ligands and various adaptors are regulated by AS, suggesting
broad roles in controlling apoptosis (Schwerk and Schulze-
Osthoff, 2005). Many apoptosis regulators, including Bcl2-like
proteins, are proto-oncogenes that contribute to apoptosis
resistance in cancer (Letai, 2008; Fesik, 2005). Modulation of
apoptotic factors by targeting the splicing machinery is thus an
attractive strategy to facilitate tumor cell death. Furthermore,
while the divergent functions of Bcl-x and Mcl1 isoforms in
apoptosis are well established, the physiological contexts and
upstream regulation of their expression are poorly defined.Cell 142, 625–636, August 20, 2010 ª2010 Elsevier Inc. 625
These unanswered questions illustrate a pervasive challenge in
defining physiological contexts of AS regulation, because
strategies for systematic evaluation of upstream regulation are
limited.
Genome-scale screening of RNA regulatory events is compli-
cated by the difficulty of visualizing RNAs in vivo, and the tech-
nical infeasibility of high-throughput measurements by RT-PCR
and other methods. Splicing-sensitive fluorescent reporters are
an alternative strategy that produce a robust, visual output suit-
able for screening efforts (Stoilov et al., 2008; Warzecha, et al.,
2009; Orengo et al., 2006). Here, we present high-throughput
assays that recapitulate physiological regulation of Bcl-x and
Mcl1 AS. In a whole-genome siRNA screen, we identified new
factors that regulate the balance of anti- and proapoptotic splice
isoforms, with striking enrichment for cell-cycle factors. These
results define functional interactions between the cell cycle
and splicingmachineries in human cells thatmanifest in a coordi-
nated program of AS controlling apoptosis.RESULTS
Reporter Assays for Bcl-x andMcl1 Alternative Splicing
To develop splicing assays for high-throughput analysis, we de-
signed splicing-sensitive reporters for the Bcl2 family apoptosis
regulators Bcl-x and Mcl1. 50 untranslated region (UTR), open
reading frame (ORF), and intervening intron sequences for Bcl-x
and Mcl1 were cloned in C-terminal fusions with Venus (yellow)
and mCherry (red) complementary DNAs (cDNAs), respectively
(Figure 1A). In HeLa cells, these constructs expressed long and
short spliced mRNAs at ratios similar to endogenous mRNAs
(Figure 1B). To render constructs splicing-sensitive, premature
termination codons (PTCs) were introduced in alternative exon
regions exclusive to long splice forms. As expected, PTCs elim-
inated expression of long protein variants, but short forms were
retained (Figure 1C).
To produce screen assay cell lines, splicing reporters were
stably transfected into HeLa cells alongwith a constitutivemCer-
ulean fluorescent protein (CFP) construct. All constructs used
the human EF1a promoter, which contains a 50 UTR intron,
allowing dual measurements of minigene splicing and a constitu-
tively spliced CFP reporter under identical control. To test the
Bcl-x reporter line, we verified that siRNA-depletion of known
regulator SF3B1 increased Bcl-xS-Venus expression relative to
a non-targeting control (Figure 1D, left panels) (Massiello et al.,
2006). Immunoblotting confirmed efficient siRNA knockdown
of SF3B1, and upregulation of Bcl-xS-Venus reporter protein
(Figure 1E). RT-PCR confirmed upregulation of the Bcl-xS-
Venus mRNA (Figure 1F). Finally, RT-PCR analysis of endoge-
nous Bcl-x transcript in HeLa cells verified that SF3B1 knock-
down shifted splicing toward Bcl-xS, demonstrating congruous
regulation of minigene and endogenous splicing (Figure 1G,
upper panel).
We had no a priori knowledge of Mcl1 regulators, but SF3B1
knockdown also upregulated Mcl1S-mCherry in the splicing
assay, establishing a positive assay control (Figure 1D, right
panels). Analysis of endogenous Mcl1 verified this shift toward
Mcl1S (Figure 1G, lower panel).626 Cell 142, 625–636, August 20, 2010 ª2010 Elsevier Inc.High-Throughput siRNA Screens for Alternative
Splicing Regulators
To identify regulators ofBcl-x AS, >21,000 siRNA pools targeting
known and predicted human genes were screened for upregula-
tion of the Bcl-x reporter (Figure 2A). Three hundred and sixty-
nine positive hits were identified with a Support Vector Machine
(SVM) model that determined reproducibility (i.e., ‘‘confidence’’)
across triplicates and signal ‘‘strength’’ relative to positive and
negative control siRNAs (Figure 2B, and Figure S1 and Table S1
available online). Hits had strong gene ontology (GO) enrich-
ments for mRNA splicing/processing, protein kinase signaling,
cytoskeleton association, and cell-cycle functions (Figure 2C).
Importantly, the screen blindly recovered positive control
SF3B1 and several of its interactors.
For validation, hits were retested in the screen assay with
four individual siRNAs from deconvoluted SMARTpools. Two
hundred and seventy-four of 369 factors validated with at least
one siRNA, and 160 validated with two or more (Figure 2A and
Table S2). In the primary and validation screens, Bcl-x-Venus
expression correlated significantly with cell death (Figures S2A
and S2C). Venus showed no systematic correlation to CFP,
indicating that nonspecific promoter effects were not a major
source of positives (Figures S2B and S2F). In the validation
screen, apoptosis was tracked by Annexin-V-Cy5 staining and
showed strong coupling to proapoptotic Bcl-x splicing and cell
death (Figures S2D and S2E). Functional enrichments, notably
splicing and cell-cycle regulation, were similar between vali-
dated hits and the primary screen (Figure 2C). Subsequent anal-
yses focused on ‘‘high-confidence’’ factors validated with two
or more siRNAs. We focused specifically on aurora kinase A
(AURKA) and other mitotic regulators because of their strong
functional enrichment and their novelty in the context of splicing
regulation.
Physiological function for screen hits was confirmed by
analysis of endogenous Bcl-x AS in HeLa cells. siRNAs against
19 factors were tested, and 16 (85%) significantly shifted
Bcl-x splicing toward Bcl-xS (Figure S3A). The magnitude of
these shifts matched or exceeded fold changes that promote
apoptosis in various cell types, indicating physiological signifi-
cance (Mercatante et al., 2002; Taylor et al., 1999). As further
indication of this significance, AURKA knockdown strongly
shifted endogenous Bcl-x protein toward Bcl-xS (Figure S3B).
This shift was larger than the corresponding mRNA shift, sug-
gesting an amplification effect during translation. Regulation of
endogenous Bcl-x by AURKA and other hits also confirmed in
MCF7 (breast adenocarcinoma) and PANC1 (pancreatic carci-
noma) cells (Figure S3C). These lines differ markedly in steady
state AURKA levels, with MCF7 (like HeLa) expressing high
levels, and PANC1 levels closer to ‘‘normal’’ tissue (Ross et al.,
2000). Thus, splicing regulation by AURKA inhibition was not
restricted to HeLa cells and occurred irrespective of steady state
AURKA levels.
Apoptosis Suppression Defines Direct Regulators
of Bcl-x Alternative Splicing
In screening experiments, proapoptotic Bcl-x splicing correlated
to apoptosis induction and increased cell death (Figure S2).
However, screen hits are likely to include both direct regulators
Figure 1. Bcl-x and Mcl1 Alternative
Splicing Reporters
(A) Bcl-x andMcl1minigene splicing reporters are
schematized. Green rectangles are exons, with
dark gray as alternative regions. Black lines depict
introns. Large arrows denote translation start
sites, and arrowheads show primer sets used
for qPCR. Inserted PTCs, exclusive to long (L) iso-
forms, are shown by red ‘‘stop signs.’’
(B) Minigene constructs are spliced like endoge-
nous mRNAs. Splice isoforms from minigene- or
mock-transfected (endogenous) HeLa cells were
analyzed by RT-PCR with primer sets from (A).
Because of high transient minigene expression,
cDNA from minigene samples was diluted 1:105
relative to mock (endogenous). At this dilution,
endogenous mRNAs do not contribute to prod-
ucts in the ‘‘minigene’’ lanes.
(C) A PTC introduced to the alternative exon region
eliminated Bcl-xL-Venus but not Bcl-xS-Venus
protein expression. HeLa cells were transfected
with Bcl-x-Venus (PTC-) or Bcl-x-Venus-PTC
(PTC+) constructs, and lysates were analyzed by
western with indicated antibodies. Migration of
isoforms is indicated to the left of images (last
two lanes overexposed to show Bcl-xS-Venus).
(D) SF3B1 knockdown activated proapoptotic
splicing of Bcl-x and Mcl1 reporters. Stable
reporter lines were transfected with SF3B1 or non-
targeting siRNA pools and imaged in the indicated
channels. SF3B1 knockdown increased minigene
expression versus controls in both cases. SF3B1
depletion also decreased CFP modestly, possibly
reflecting a role in splicing the EF1a intron. Subse-
quent experiments showed this effect on CFP
expression was restricted to SF3B1 (see Figures
S2B and S2F).
(E) Upregulation of Bcl-xS bySF3B1 depletion was
confirmed by western analysis. Lysates from cells
treated as in (D) were analyzed with antibodies
indicated to the left of images. SF3B1 knockdown
depleted SF3B1 and increased Bcl-xS-Venus
relative to controls.
(F) Results in (D) and (E) were verified at the RNA
level by RT-PCR. Migration of Bcl-xS, Bcl-xL (PTC
causes nonsense-mediated decay), and GAPDH
(loading control) are indicated to left of the images.
(G) Results in (D), (E), and (F) model the regulation of endogenous Bcl-x andMcl1mRNAs. Unmodified HeLa cells were transfected with SF3B1 or control siRNAs.
RT-PCR analysis confirmed that SF3B1 knockdown favored short, proapoptotic forms. S/L ratios are quantified to the right of the images; values are the means of
three independent measurements ± SD, normalized to controls.of Bcl-x splicing and factors that influence splicing indirectly via
upstream activation of proapoptotic pathways (Figure 3A). To
define systematically the relationship of screen hits to apoptosis,
we retested all 274 validated regulators inBcl-x reporter cells en-
gineered to overexpress Bcl2. Bcl2 overexpression suppresses
mitochondrial permeablization and hence canonical apoptosis
progression (Kroemer, 1997). Importantly, Bcl2 directly antago-
nizes the function of Bcl-xS, so this strategy also suppresses
potential downstream effects of Bcl-xS-Venus produced by
the reporter construct. We predicted that Bcl2 overexpression
would attenuate the effects of proapoptotic siRNAs that alter
Bcl-x splicing as part of a general proapoptotic response, but
not siRNAs that target more direct regulators of splicing.Supporting the latter prediction, depletion of direct regulator
SF3B1 increased reporter expression despite Bcl2 overexpres-
sion (Figure 3B).
Thirty-three percent of 160 high-confidence Bcl-x regulators
were totally suppressed by Bcl2 overexpression (Table S3). For
example, Bcl2 suppressed both cell death and changes in
Bcl-x splicing in response to depleting mRNA export factors
NXF1 or NUPL2 (Figure 3C). By contrast, 67% of factors,
including AURKA, showed partial or no suppression of proapop-
totic Bcl-x splicing, despite the fact that cell counts showed effi-
cient suppression of cell death. Thus, AURKA, not previously
implicated in splicing regulation, functioned independently of
Bcl2, whereas mRNA export factors, which directly interactCell 142, 625–636, August 20, 2010 ª2010 Elsevier Inc. 627
Figure 2. Whole-Genome siRNA Screen for
Regulators of Bcl-x Alternative Splicing
(A) Screening, analysis, and hit selection are sche-
matized. Of 369 primary hits, 274 revalidated. The
pie chart indicates how many of 274 validated hits
reconfirmed with one, two, three, or four siRNAs.
One hundred and sixty ‘‘high-confidence’’ hits
validated with two or more siRNAs (see the
Extended Experimental Procedures for complete
analysis methods).
(B) SVM probability scores are plotted for the
whole-genome siRNA screen, with confidence
on the x axis and strength on the y axis. The blue
region shows the SVM cutoff for hit selection
(see Figures S1, S2, and S3 and Tables S1 and
S2 for detailed analysis and validation).
(C) GO functional enrichments from primary, reva-
lidated (one ormore siRNAs), and high-confidence
(two or more siRNAs) hits are shown, plotted by
relative statistical significance.
See also Figures S1, S2, and S3 and Tables S1
and S2.with the spliceosome, were suppressed. Overall, most mRNA-
splicing and cell-cycle regulators showed no or partial sup-
pression (Figure 3D). Suppressed factors were enriched for
functions in transcription, while signaling factors spanned both
categories.
Discovery ofMcl1 Alternative Splicing Regulators
To explore functional coordination of apoptotic AS events, we
determined all Bcl-x regulators that also control functionally
analogous AS of Mcl1. Fifty-two of 160 ‘‘high-confidence’’
factors regulated both events, and we validated a subset on
endogenous Mcl1 (Figure 4A, Figure S4, and Table S4). Cell-
cycle functions were enriched for factors that coregulated
Bcl-x and Mcl1, but not factors that regulated only Bcl-x
(Figure 4A). Similarly, common regulators were disproportion-
ately enriched for splicing functions versus those that only regu-
lated Bcl-x. This result indicates extensive coregulation of Bcl-x
and Mcl1 by cell-cycle and splicing factors. In contrast, tran-
scription regulators were enriched only forBcl-x. Figure 4B sche-
matizes hits in the Bcl-x andMcl1 screens with known or postu-
lated functions in mRNA metabolism. Hits included ‘‘core’’
spliceosome components in Sm ring domains and snRNPs, as
well as hnRNP and SR proteins. Interestingly, factors acting
late in spliceosome assembly, including U5 snRNP components
and factors previously linked to cell-cycle regulation (e.g.,
CDC40, CDC5L), scored positively for both Bcl-x and Mcl1
(Makarova et al. 2004).
As an unbiased analysis of Mcl1 AS, we tested siRNA pools
for >700 human kinases and phosphatases in theMcl1 screening
assay. Common regulators for Bcl-x and Mcl1 included cell-628 Cell 142, 625–636, August 20, 2010 ª2010 Elsevier Inc.cycle kinases AURKA, PLK1, and WEE1
(Figure 4C and Table S5). Further, BUB1
scored strongly for Bcl-x and weakly
positive for Mcl1, though the latter did
not surpass the confidence threshold.
Conversely, CDK1 (CDC2) was stronglypositive for Mcl1, and weakly so for Bcl-x. These data indepen-
dently confirm Mcl1 AS regulation by cell-cycle disruption.
Coupling of Cell-Cycle Control and Alternative Splicing
The screen identified many cell-cycle factors, including cancer
therapy targets AURKA, PLK1, and survivin (BIRC5). Protein
interaction network analysis of screen hits revealed AURKA-
centered interactions spanning the cell cycle, spliceosome,
and tumor suppressors (Figure 5A). As independent validation
of this regulation, nocodazole, an inhibitor of microtubule
polymerization, and aurora kinase inhibitors ZM447439 and
VX-680 strongly induced Bcl-xS formation in a dose-dependent
manner (Figure 5B). By contrast, the broad-spectrum kinase
inhibitor staurosporine induced apoptosis but not Bcl-xS forma-
tion, demonstrating specific regulation by cell-cycle inhibitors.
ZM447439 and VX-680 inhibit the three mammalian aurora
kinases AURKA, AURKB, and germline-restricted AURKC. How-
ever, ZM447439 is 20-fold more potent toward AURKB than
AURKA in vitro, while VX-680 is 30-fold more potent against
AURKA (Ditchfield et al., 2005; Harrington et al., 2004). Since
Bcl-x splicing regulation in screening assays was AURKA
specific, VX-680 was used subsequently because of its higher
specificity for AURKA. Importantly, nocodazole and VX-680
treatment also shifted endogenous Bcl-x and Mcl1 splicing
(Figure S5).
In flow cytometry experiments, aurora inhibitors induced
mitotic arrest concomitant with upregulation of theBcl-x reporter
(Figure 5C). Bcl-xS-Venus levels in actively cycling G2/M cells
were slightly higher than in G1, but the difference was not signif-
icant compared to arrested cells (Figure 5D). In addition, S phase
Figure 3. Apoptosis Inhibition by Bcl2 Suppressed a Subset of Bcl-x Regulators
(A) Screen hits (lightning bolts) may affectBcl-xAS bymany potential mechanisms. Regulationmay be direct, such as (1) direct suppression ofBcl-xS formation or
(2) facilitation ofBcl-xL. Indirect or downstream regulators may (3) promote cell survival pathways or (4) suppress proapoptotic pathways. We predicted that Bcl2
overexpression would suppress the splicing regulatory effect of siRNAs targeting indirect mechanisms, but not direct regulators.
(B) Bcl2 overexpression did not suppress the effect of SF3B1 depletion, consistent with direct regulation of Bcl-x splicing.
(C) Bcl2 suppressed the effect of siRNAs against mRNA export factors NXF1 and NUPL2, but not AURKA, on Bcl-x splicing (compare Venus images between
‘‘wild-type’’ and ‘‘Bcl2 overexpression’’). By contrast, Bcl2 suppressed cell death in all cases (compare DAPI images).
(D) Thirty-three percent of hits were suppressed by Bcl2 overexpression, while 67% showed partial to no suppression. GO functional enrichments within these
subsets are shown with p values (see Table S3).
See also Table S3.arrest by double-thymidine block did not affect Bcl-xS-Venus
levels, so the splicing response was specific to mitotic arrest
(Figure 5E). Since transcription and splicing are primarily
silenced in M phase (Shin and Manley, 2002), we considered
two possibilities: (1) splicing changes preceded arrest or (2)
a subset of cells underwent an abnormal division prior to full
arrest, leading to a proapoptotic stress response. To test the
latter scenario, cells were synchronized by double-thymidine
block, released, and treated with VX-680. Venus fluorescence
was measured 16 hr after thymidine release, thus ruling out an
intervening mitotic cycle. Figure 5F shows the splicing response
to VX-680 in synchronized cells was comparable to asynchro-
nous cells. Apoptosis induction by staurosporine caused no
splicing response, regardless of synchronization. These results
show that stimuli that activate G2/M and spindle checkpoints
trigger proapoptotic Bcl-x splicing, but the response precedes
actual arrest.
Downstream Mechanisms of Splicing Regulation
To identify direct splicing regulators downstream of cell-cycle
inhibition, we examined expression of splicing factors upon
AURKA knockdown, focusing on strong screen hits or factors
previously linked to Bcl-x splicing (Figure S6A). Among these
factors, only ASF/SF2 (SFRS1)—an SR protein previously linked
to cell-cycle regulation and a strong hit in the primary screen—showed specific downregulation upon AURKA knockdown
(Figure 6A) (Li et al., 2005). Inhibition of AURKA with VX-680
also resulted in dose-responsive downregulation of ASF/SF2
(Figure 6B).
ASF/SF2 mRNA was not significantly reduced upon AURKA
inhibition, ruling out transcriptional downregulation or effects
on RNA stability (Figure S6B). However, VX-680 treatment
reduced exogenous green fluorescent protein (GFP)-tagged
ASF/SF2 in a manner similar to endogenous ASF/SF2, indicating
posttranslational turnover as the main source of ASF/SF2 deple-
tion (Figure 6C). AURKA inhibition also induced ASF/SF2 down-
regulation in apoptosis-resistant cells that overexpress Bcl2
(Figure S6C). Therefore, this regulatory pathway functions in
cells where apoptosis is suppressed, consistent with our finding
that AURKA knockdown shifts Bcl-x splicing when apoptosis is
suppressed (Figure 3C).
To determine whether Bcl-x is a direct target of ASF/SF2, we
used the CLIPmethod (ultraviolet [UV] crosslinking and immuno-
precipitation) to analyze RNAs bound directly by ASF/SF2
in vivo. RNP complexes were covalently crosslinked in living
cells by UV exposure, and ASF/SF2-RNA complexes were
immunopurified (Figure 6D). RT-PCR analysis showed significant
enrichment of Bcl-x mRNA in ASF/SF2-RNA immunoprecipita-
tions (IPs) versus an irrelevant IgG control, along with Mcl1 and
previously known target TPX2 (Figure 6E) (Sanford et al., 2009).Cell 142, 625–636, August 20, 2010 ª2010 Elsevier Inc. 629
Figure 4. Coordinated Regulation of Bcl-x and Mcl1 Alternative
Splicing
(A) Bcl-x screen hits were tested forMcl1 regulation to identify common regu-
lators. High-confidence hits are depicted as a Venn diagram, with GO enrich-
ments listed with p values in the subsets where they were most significantly
enriched (see Figure S4 and Table S4).
(B) Spliceosome-associated proteins (SAPs) that were Bcl-x screen hits are
shownwith established physical interactions and functional roles. Blue ellipses
represent known RNP or protein complexes; pink ellipses contain functionally
or structurally related factors. Low-confidence hits are italicized. Factors in
gray rectangle have unknown roles in splicing but were identified in proteomic
analyses or are similar to known splicing factors (Chen et al., 2007). Factors are
marked as follows: *, high-confidence hit forMcl1; underlined, phosphorylated
in mitosis; +, putative AURKA target; x, putative CDK1 target; and #, putative
PLK1 target (Dephoure et al., 2008).
(C) Hits from a kinase/phosphatase screen for Mcl1 splicing regulation are
shown, with corresponding Bcl-x regulators. A cutoff of p < 105 in three repli-
630 Cell 142, 625–636, August 20, 2010 ª2010 Elsevier Inc.APAF1 and TNFSF13 mRNAs were detectable in input but not
ASF/SF2 IPs, demonstrating that crosslinking was specific.
Our data show direct regulation of Bcl-x and Mcl1 splicing by
ASF/SF2 and downregulation of ASF/SF2 by AURKA inhibition.
To test whether ASF/SF2 functions downstream of AURKA inhi-
bition, we examined whether exogenous ASF/SF2 expression
could ‘‘rescue’’ the splicing response to AURKA inhibition.
Bcl-x reporter cells were transfected with mCherry-tagged
constructs expressing wild-type (WT) ASF/SF2 or a variant lack-
ing the second RNA recognition motif (DRRM2) domain. After
VX-680 treatment, the Bcl-x splicing response in cells express-
ing ASF/SF2-WT was reduced50% relative to cells expressing
DRRM2 or mCherry alone (Figure 6F). CLIP of exogenous GFP-
tagged ASF/SF2 constructs confirmed deficient recognition of
endogenous Bcl-x mRNA by the DRRM2 mutant (Figure 6G)
(Ca´ceres et al., 1997). Therefore, enforced ASF/SF2 expression
rescued the effect of AURKA inhibition on Bcl-x splicing, and
rescue was dependent on intact splicing regulatory function.
ASF/SF2 regulates apoptosis globally in response to cell-cycle
inhibition. Consistent with previous reports, siRNA depletion of
ASF/SF2 activates markers of apoptosis (e.g., Annexin-V stain-
ing, DNA fragmentation, and caspase cleavage) (data not shown)
(Li et al., 2005; Karni et al., 2007). To analyze apoptosis regula-
tion by ASF/SF2 in the context of cell-cycle disruption, we
depleted ASF/SF2 by RNAi and analyzed apoptosis markers
upon AURKA inhibition with VX-680. ASF/SF2 depletion
enhanced caspase activation and Annexin-V staining relative
to a nontargeting siRNA control (Figures 7A and 7B). In addition,
we compared the effects of ASF/SF2 depletion to the depletion
of two splicing factors (SRPK1 and SNRP70) that had no signif-
icant effect on endogenous Bcl-x splicing and a third factor
(Sam68) that has antagonistic effects to ASF/SF2 on Bcl-x
splicing (Figure S3A and Table S1) (Paronetto et al., 2007).
ASF/SF2 depletion sensitized cells to VX-680-induced apoptosis
relative to SRPK1, SNRP70, or Sam68 depletion. In contrast,
ASF/SF2 depletion did not enhance staurosporine-induced
apoptosis relative to SRPK1, SNRP70, or Sam68 depletion
(Figure S6D). We could not reliably analyze the effects of en-
forced ASF/SF2 expression on apoptotic markers because over-
expression was toxic in the time frame required for this analysis.
In sum, ASF/SF2 loss-of-function triggers apoptosis and specif-
ically sensitizes cells to apoptosis induced by AURKA inhibition.
To examine broader functions of AS in this apoptotic
response, we analyzed caspase-9 (CASP9) and caspase-2
(CASP2) mRNAs, which produce short (S), antiapoptotic, or
long (L), proapoptotic isoforms (Schwerk and Schulze-Osthoff,
2005). Depletion of ASF/SF2 and AURKA favored proapoptotic
CASP9 splicing (Figure 7C) (Massiello and Chalfant, 2006). In
addition, ASF/SF2 depletion favored proapoptotic CASP2
splicing, although AURKA knockdown had no significant effect.
We extended our analysis to additional factors with diverse
apoptotic functions and AS patterns, including exon skipping,
alternative 50 ss use, and intron retention. Splice isoforms were
measured with an isoform-sensitive qPCR strategy uponcates, or p < 107 in two replicates was applied (see Table S5). Cell cycle
factors are underlined.
See also Figure S4 and Tables S4 and S5.
Figure 5. Alternative Splicing Regulation Is Coupled to Cell-Cycle Control
(A) Screen hits span an AURKA-centered protein interaction network. Circles (‘‘nodes’’) depict proteins, connected by lines (‘‘edges’’) representing validated
protein-protein interactions. A maximum of two nonhit bridges was permitted to connect hits to AURKA, as described in the Extended Experimental Procedures.
(B) Drugs disrupting the cell-cycle promote proapoptotic Bcl-x AS. Bcl-x reporter cells were treated with nocodazole, aurora inhibitors VX-680 or ZM447439, or
staurosporine for 18 hr. 3-fold dilution series were tested with the following maximum concentrations: 200 nM nocodazole, 10 mMVX-680, 30 mMZM447439, and
33 nM staurosporine. Percent-Venus-positive values for drug treatments were normalized to DMSO treatments; plotted values reflect means of 8–12 measure-
ments ± SD. Nocodazole, VX-680, and ZM447439, but not staurosporine, caused significant proapoptotic shifts in Bcl-x splicing (p < 0.001). LD50 ranges derived
from cell counts are shown below the x axis. Wells with >33 nM staurosporine had >95% death, so they were not quantified (see Figure S5).
(C) Aurora inhibitors induced mitotic arrest coupled with proapoptotic Bcl-x splicing. Bcl-x reporter cells were treated with 3 mM VX-680, 10 mM ZM447439, or
DMSO, stained with propidium iodide, and analyzed for DNA content and Venus fluorescence by flow cytometry.
(D) Asynchronous, actively cycling cells from (C) show little to no Bcl-x splicing fluctuations relative to arrested cells.
(E) S phase arrest by double thymidine block did not alter Bcl-x splicing, indicating specificity for mitotic arrest. Cells were analyzed as in (C).
(F) Bcl-x splicing regulation precedes mitotic arrest. Asynchronous or thymidine-synchronized cells from (E) were treated with the indicated inhibitors or DMSO.
Cells were analyzed by automated microscopy 16 hr after thymidine release, precluding an intervening round of mitosis for synchronized cells. The response in
presynchronized cells confirms a splicing shift upstream of mitotic arrest.
See also Figure S5.knockdown of various screen hits, revealing widespread
changes in splicing upon silencing of cell-cycle regulators
(Figures 7D). This approach is only semiquantitative, so we
focused on identifying biologically robust events by Z score anal-
ysis of four independent experiments (Figures S7A and S7B).
Hierarchical clustering of knockdown profiles revealed overlap-
ping regulation by cell-cycle kinases AURKA, CDC2, and
BUB1. In addition, splicing factor profiles grouped by validated
spliceosomal interactions; the U2 snRNP factors SF3B1 and
SF3A1 overlapped significantly, as did U5 factors PRPF6 and
U5-200K. Interestingly, ASF/SF2 targets clustered with AURKA
and kinetochore component NDC80, suggesting overlapping
regulation in this specific set of mRNAs. As confirmation of direct
regulation, binding of ASF/SF2 to selected targets CASP9,
CASP2, ATG4, and BMF was established by CLIP (Figure S7D).DISCUSSION
Genome-wide Identification of Alternative Splicing
Regulators in Human Cells
We developed a strategy for systematic, high-throughput anal-
ysis of AS regulation in human cells. Our siRNA screens identi-
fied many spliceosomal regulators of Bcl-x and Mcl1 splicing,
as well as functional connections to cell-cycle control, cytoskel-
eton dynamics, and signal transduction (Figure 2C). Strong func-
tional enrichment for known splicing factors was an encouraging
indication of specificity. In addition, a high validation rate of
screen hits on endogenous AS indicated faithful modeling of
physiological regulation in our reporter assays (Figure S3).
Broadly, our efforts expand the catalog of factors linking
mRNA metabolism and apoptosis and provide a platform forCell 142, 625–636, August 20, 2010 ª2010 Elsevier Inc. 631
Figure 6. ASF/SF2 Regulates Splicing
Downstream of AURKA
(A) siRNA depletion of AURKA downregulated
ASF/SF2. Cells were transfected with two different
siRNAs for AURKA or AURKB, or control siRNAs.
Lysates were analyzed by western analysis for
indicated factors. No other splicing factors mea-
sured in these samples showed significant
changes (Figure S6A), indicating specificity for
ASF/SF2.
(B) VX-680 treatment downregulated ASF/SF2 in
a dose-dependent manner.
(C) ASF/SF2 is downregulated posttranslationally
upon AURKA inhibition (see also Figure S6B).
HeLa cells were transfected with a GFP-ASF/SF2
construct, and then treated with VX-680 or
DMSO. Western analysis showed that VX-680
downregulated exogenous ASF/SF2, indicating
posttranslational turnover. ASF/SF2 downregula-
tion also occurred in apoptosis-resistant cells
overexpressing Bcl2 (see Figure S6C).
(D) Visualization of ASF/SF2-RNA complexes by
CLIP is shown. RNP complexes were UV cross-
linked in live HeLa cells, ASF/SF2 was immuno-
purified, and RNA was end labeled with g-32P-
ATP. Complexes were run on SDS-PAGE and
visualized by autoradiography. Noncrosslinked
ASF/SF2 (UV lane) was also labeled, as
observed in Sanford et al. (2009).
(E) ASF/SF2 directly bindsBcl-x andMcl1mRNAs.
RT-PCR analysis of ASF/SF2-bound RNAs
showed significant enrichment of Bcl-x, Mcl1,
and known target TPX2 versus an irrelevant IgG
control. Values are the means of three indepen-
dent measurements ± SD.
(F) Exogenous expression of ASF/SF2 attenuated
the effect of AURKA inhibition on Bcl-x splicing.
Bcl-x reporter cells were transfected with
mCherry-tagged ASF/SF2, a mutant lacking the
second RRM domain (DRRM2), or mCherry alone.
Eighteen hours after transfection, cells were
treated with 3 mm VX-680 or DMSO for 24 hr.
The fraction of Venus-positive cells among mCherry-positive cells was determined by automated microscopy. VX-680-treated samples were background cor-
rected by subtraction of values from DMSO treatment. Values are the means of three separate measurements ± SD, expressed relative to the mCherry-trans-
fected control. ASF/SF2-WT attenuated theBcl-x response to VX-680 by50% versusDRRM2. CFP expressionwas not affected, indicating specific attenuation
of Bcl-x splicing.
(G) ASF/SF2-DRRM2 shows deficient association with Bcl-x and Mcl1 mRNAs. CLIP analysis of exogenous, GFP-tagged ASF/SF2-WT or -DRRM2 was per-
formed with a-GFP antisera. Values are the means of three independent measurements ± SD.
See also Figure S6.future high-throughput analyses of mRNA processing in living
cells.
Screen hits spanned essential processes, such as transcrip-
tion, cell division, and prosurvival signaling, with extensive
mechanistic links to apoptosis, implicating splicing regulation
in diverse proapoptotic pathways. The strong correlation of
Bcl-xS formation with apoptosis induction and cell death further
support a physiological function for splicing regulation in
apoptosis (Figure S2). To investigate the functional connection
between splicing regulation and apoptosis, we retested factors
in cells rendered resistant to apoptosis by exogenous Bcl2
expression (Figure 3). Surprisingly, cell-cycle factors, like most
spliceosomal factors, were generally not affected by Bcl2
expression. Therefore, functional coupling of cell-cycle disrup-632 Cell 142, 625–636, August 20, 2010 ª2010 Elsevier Inc.tion to proapoptotic splicing remained intact in cells in which
the canonical apoptosis pathway was suppressed. This finding
suggests that coordinated, proapoptotic splicing could be
exploited to target apoptosis-resistant cell populations, such
as tumors.
Our screening experiments also revealed functional coordina-
tion of proapoptotic splicing events. Fifty-two of 160 ‘‘high-confi-
dence’’ Bcl-x regulators affected functionally analogous splicing
of Mcl1, and common regulators were disproportionately
enriched for splicing and cell-cycle functions (Figure 4A). Over-
lapping spliceosomal regulators of Bcl-x and Mcl1 included
‘‘alternative splicing factors’’ (e.g., hnRNPs and SR proteins)
and ‘‘core’’ spliceosome components spanning most steps in
spliceosome assembly (Figure 4B). Interestingly, U5 snRNP
Figure 7. An Apoptotic Alternative Splicing
Program Linked to Cell-Cycle Control
(A) ASF/SF2 downregulation triggers apoptosis
and sensitizes cells to apoptosis induction by
AURKA inhibition. HeLa cells were transfected
with indicated siRNAs, incubated to allow factor
depletion, and then treated with varying concen-
trations of VX-680. Apoptosis was measured via
cleavage of a fluorescent caspase-3 substrate.
Depletion of ASF/SF2, but not SRPK1, SNRP70,
or Sam68, sensitized cells to VX-680-induced
apoptosis. This selective sensitization by ASF/
SF2 depletion was not observed for staurospor-
ine-induced apoptosis (see Figure S6D). Data
reflect the means of three independent transfec-
tions ± SD.
(B) Analysis in (A) was repeated with Annexin-V
staining used as the apoptosis marker.
(C) CASP9 and CASP2 AS were analyzed in HeLa
cells by qPCR after transfection with the indicated
siRNAs. Relative levels of proapoptotic isoform (L)
normalized to negative controls are shown. Values
are the means of three independent measure-
ments ± SD.
(D) Results of AS profiling by real-time qPCR are
shown in a heat-map of Z scores averaged across
four biological replicates, along with unsupervised
hierarchical clustering (see Figure S7 for an
expanded view and validation of these data).
(E) A model of cell-cycle arrest coupled to apo-
ptosis via AS is shown. We propose anticipatory,
proapoptotic splicing decisions in interphase that
later promote apoptosis in arrested cells. Light-
ning bolts represent siRNAs, drugs, or other
stimuli that disrupt the cell cycle and promote
proapoptotic splicing of Bcl-x, Mcl1, CASP9, and
other targets.
See also Figures S6 and S7.and associated factors that function late in spliceosome
assembly affected splice-site choice for Bcl-x, Mcl1, and other
mRNAs (Figures 4B, 7C, and 7D). Current mechanistic models
support splice-site pairing early in spliceosome assembly upon
U2 snRNP recruitment (Dassah et al., 2009). Our findings
suggest that perturbations of late steps in spliceosome func-
tion may promote remodeling of splice-site choice downstream
of the rate-limiting steps that normally determine splicing
decisions.
Cell-Cycle Disruption Coupled to Proapoptotic
Alternative Splicing
Our screen for AS regulators identified factors involved in mitotic
spindle assembly, kinetochore and centromere dynamics,
microtubule transport, centrosome duplication and dynamics,
and cell division (Figure 5A). Well-characterized pharmacolog-
ical inhibitors, notably for AURKA, confirmed functional coupling
of cell-cycle and splicing regulation (Figure 5B and Figure S5).
In flow cytometry experiments, proapoptotic Bcl-x splicing was
coupled to mitotic arrest, but not S phase arrest or G2/M in
actively cycling cells (Figures 5C–5E). Since prevailing evidence
supports suppression of transcription and splicing in mitosis, it is
unlikely that the observed response initiates in mitotically ar-rested cells (Shin and Manley, 2002). Moreover, when cells
were presynchronized to preclude an intervening cell division,
VX-680 still induced a robust splicing response (Figure 5F).
Therefore, this splicing regulation precedes mitotic arrest,
indicating accumulation of prodeath factors in anticipation of
G2/M and/or mitotic spindle checkpoints. Since cell-cycle
disruption also promoted a proapoptotic switch in CASP9
splicing and altered splicing of other apoptotic regulators, this
regulation likely extends to many coregulated mRNAs (Figures
7C and 7D).
Many previous studies have linked cell-cycle and splicing
regulation, reaching back to the seminal isolation of cell-division
cycle (CDC) loci in S. cerevisiae that encode spliceosome
components, including factors (CDC5L and CDC40) identified
here. Recent genetic and proteomic analyses of mitotic spindle
assembly have reasserted the notion that the cell-cycle and
splicing machineries are intertwined, but functional conse-
quences have not been established (Bjo¨rklund et al., 2006, Rines
et al., 2008). We observe coordinated proapoptotic splicing
upon inhibition of key cell-cycle factors, but preceding mitotic
arrest, indicating anticipatory upregulation of prodeath factors
that may subsequently propagate apoptosis in arrested cells.
Since arrested cells cannot mount de novo transcriptional andCell 142, 625–636, August 20, 2010 ª2010 Elsevier Inc. 633
splicing responses, this finding suggests a genetic mechanism
for cell-cycle checkpoint response.
ASF/SF2 Regulates an Apoptotic Splicing Network
We present evidence that ASF/SF2 downregulation mediates
a proapoptotic splicing response to cell-cycle disruption.
ASF/SF2 was a hit in the Bcl-x andMcl1 screens, and its overex-
pression was previously shown to favor Bcl-xL formation (Paro-
netto et al., 2007). AURKA inhibition triggered posttranslational
turnover of ASF/SF2, but not other SR proteins or splicing factors
identified in the screen (Figures 6A–6C and Figure S6A). In addi-
tion, ASF/SF2 directly binds Bcl-x and Mcl1 mRNAs, and its
enforced expression attenuated the effect of AURKA inhibition
on Bcl-x splicing (Figures 6D–6G).
ASF/SF2 regulation extends beyond Bcl-x to global regulation
of apoptosis (Li et al., 2005). ASF/SF2 depletion, but not deple-
tion of several splicing factors that were not validated screen
hits, sensitized cells to apoptosis induction by AURKA inhibition
(Figures 7A and 7B). In contrast, ASF/SF2 depletion did not
specifically enhance apoptosis in response to staurosporine
(Figure S6D). ASF/SF2-mediated splicing regulation extended
to other functional targets, including CASP9, which underwent
a proapoptotic splicing shift upon depletion of AURKA and
ASF/SF2 (Figure 7C). Our analysis of some 25 additional AS
targets revealed overlapping effects of AURKA and ASF/SF2
inhibition (Figure 7D). The fact that some mRNAs (e.g., CASP2)
did not respond identically to AURKA and ASF/SF2 knockdown
may reflect differential effects of targeting upstream versus
direct regulators of splicing, or the activity of additional, uniden-
tified splicing regulators. Nonetheless, these experiments
strongly indicate that ASF/SF2 downregulation globally shifts
alternative splicing patterns to promote apoptosis upon disrup-
tion of the cell cycle.
Alternative Splicing in a Global Context
Our data link coordinated proapoptotic splicing to activated cell-
cycle checkpoints (Figure 7E). These findings are relevant to
basic mechanisms of apoptosis in arrested cells, which are
poorly defined, and the exploitation of these pathways in cancer
therapy. Aberrant expression of AURKA and other prodivision
factors promotes spindle checkpoint abrogation, chromosomal
instability, and aneuploidy in tumors (Lapenna and Giordano,
2009). Our findings indicate that AURKA activation may also
propagate oncogenesis by promoting antiapoptotic splicing of
crucial cell-death regulators. Conversely, AURKA inhibition
elicits parallel upregulation of prodeath variants, which may
contribute to its demonstrated efficacy as a cancer drug target.
Importantly, this regulation remains intact in apoptosis-resistant
cells, suggesting functional and potential therapeutic relevance
in tumors.
ASF/SF2 downregulation triggers proapoptotic splicing and
promotes apoptosis. Importantly, ASF/SF2 is a proto-oncogene
in its own right, and its depletion is linked to genome instability
and G2/M arrest (Karni et al., 2007; Li and Manley, 2005). Our
data highlight RNA targets that may contribute to its transform-
ing properties. Taken together, these findings suggest that
ASF/SF2 has multiple, synergistic functions in controlling cell
arrest and apoptosis, underscoring its role as a central regulator634 Cell 142, 625–636, August 20, 2010 ª2010 Elsevier Inc.of mRNA metabolism in cancer. Finally, it bears reiterating that
our systematic screening approach was the original source of
these biological insights, as well as many new regulators and
functional connections not expounded here. We believe future
screening efforts will be instrumental in defining global roles for
AS in physiological and disease contexts.
EXPERIMENTAL PROCEDURES
siRNA Screening
Cells were transfected in triplicate in 384-well plates with >21,000 siRNA
SMARTpools (Thermo-Fisher) for known and predicted human genes.
Seventy-two hours later, cells were fixed, DAPI stained, and imaged on the
Image Xpress Micro microscope (Molecular Devices). Cell counts (DAPI),
percent of Venus-positive cells, and average per-cell CFP signal were deter-
mined with MetaXpress software. Wells were then assigned probabilistic
‘‘strength’’ and ‘‘confidence’’ scores in the Venus channel using a support
vector machine (SVM) model trained on positive and negative control data
(Figure S1, Table S1, and the Extended Experimental Procedures). For inde-
pendent verification, plate-wide, median-normalized Z scores were also tabu-
lated. Wells with SVM strength scores with false discovery rate (FDR) <10, or
z > 2.6 were inspected visually.
Three hundred and sixty-nine positives were retested in a validation screen
with four siRNAs from deconvoluted SMARTpools. siRNAs >2 standard devi-
ations (SDs) above negative controls in the Venus channel were deemed posi-
tive (Table S2). Bcl2-overexpression and Mcl1 screens were performed and
analyzed as for the validation screen (Tables S3 and S4).
RNA Extraction and RT-qPCR
Cellular RNA was extracted with Trizol (Invitrogen) reagent, and 2.5–5 mg were
reverse transcribed with Superscript III (Invitrogen) and oligo-dT. Bcl-x, Mcl1,
CASP9, and CASP2 isoforms were analyzed by qPCR with primers flanking
alternative exon sequences. For each product, a linear range of cDNA input
was determined empirically by running of a 2-fold dilution series in 26–28 cycle
reactions. Products were run on 5% TBE-PAGE gels, stained with Sybr-Gold
(Invitrogen), and quantified with QuantityOne software (Biorad).
Real-time qPCR primer sets were designed with Primer3 webware and
tested by electrophoresis to verify correctly sized products (Table S6). Reac-
tions were prepared with Sybr-Green PCR mix (ABI), run on the ABI 7900HT
system, and quantified by a DDC(t) method. Amplicons from alternative
regions were first normalized to a constitutive amplicon from the same tran-
script. To correct for differential primer efficiencies, data were then normalized
to negative controls. Z scores were tabulated across four independent exper-
iments and clustered with Eisen Cluster 2.0.
Splicing Assays with Drug Treatments
Sources for inhibitors are in the Extended Experimental Procedures. Cells
were treated in 96-well plates for 18–24 hr and analyzed by automated micros-
copy. For flow cytometry, cells were fixed in 3% PFA/1X PBS then 70%
ethanol, permeablized in 1X PBS/0.1% Triton X-100, and stained with
20 mg/ml propidium iodide. DNA content and Venus fluorescence were
analyzed on the LSRII system (BD Biosciences).
Western Blotting
Proteins were extracted in RIPA buffer (IX PBS, 1%Triton X-100, 0.5% sodium
deoxycholate, 0.1% SDS, protease inhibitors) and quantified by Protein Dye-
Binding Assay (Biorad). Ten to fifty micrograms of total protein were run on
4%–12% Bis-Tris polyacrylamide gels (Invitrogen), transferred to PVDF
membranes, and probed with antibodies listed in Supplemental Data.
CLIP
UV crosslinking and RNP purification/visualization were performed as
described (Sanford et al., 2009). For quantification, CLIP and input samples
were treated with Proteinase K (Ambion), and RNA was extracted, reverse
transcribed, and analyzed by real-time qPCR.
Apoptosis Assays
Annexin-V-Cy5 (Abcam) staining was quantified by automated microscopy.
Caspase activation was measured with the DEVD-Nucview 488 reagent
(Biotum), which stains nuclei specifically after it is cleaved by caspase-3. Cells
were incubated for 1 hr with 2.5 mM substrate, fixed, and analyzed by auto-
mated microscopy.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Extended Experimental Procedures, seven
figures, and six tables and can be found with this article online at doi:10.1016/
j.cell.2010.07.019.
ACKNOWLEDGMENTS
We thank Junying Yuan and Robin Reed for reagents, Jodene Moore for help
with flow cytometry, and Jessica Hurt, Natalie Gilks-Farny, Daniel Ducat, Wil-
liam Senapedis, Faisal Aldaye, Deborah Flusberg, and Ian Swinburne for
thoughtful critiques and discussions. RNAi screening capability was provided
by the ICCB-Longwood screening facility at Harvard Medical School. We are
indebted to ICCB-L staff Caroline Shamu, Sean Johnston, Stewart Rudnicki,
Zac Cooper, and David Wrobel. M.J.M. was supported by funding from the
National Science Foundation. Work was supported by grant NIHGM057476
to P.A.S. from the National Institutes of Health.
Received: September 3, 2009
Revised: February 18, 2010
Accepted: June 15, 2010
Published online: August 12, 2010
REFERENCES
Akgul, C., Moulding, D.A., and Edwards, S.W. (2004). Alternative splicing of
Bcl-2-related genes: functional consequences and potential therapeutic appli-
cations. Cell. Mol. Life Sci. 17, 2189–2199.
Bjo¨rklund, M., Taipale, M., Varjosalo, M., Saharinen, J., Lahdenpera¨, J., and
Taipale, J. (2006). Identification of pathways regulating cell size and cell-cycle
progression by RNAi. Nature 439, 1009–1013.
Black, D.L. (2003). Mechanisms of alternative pre-messenger RNA splicing.
Annu. Rev. Biochem. 72, 291–336.
Blencowe, B.J. (2006). Alternative splicing: new insights from global analyses.
Cell 14, 37–47.
Ca´ceres, J.F., Misteli, T., Screaton, G.R., Spector, D.L., and Krainer, A.R.
(1997). Role of the modular domains of SR proteins in subnuclear localization
and alternative splicing specificity. J. Cell Biol. 138, 225–238.
Chen, Y.I., Moore, R.E., Ge, H.Y., Young, M.K., Lee, T.D., and Stevens, S.W.
(2007). Proteomic analysis of in vivo-assembled pre-mRNA splicing
complexes expands the catalog of participating factors. Nucleic Acids Res.
35, 3928–3944.
Cloutier, P., Toutant, J., Shkreta, L., Goekjian, S., Revil, T., and Chabot, B.
(2008). Antagonistic effects of the SRp30c protein and cryptic 50 splice sites
on the alternative splicing of the apoptotic regulator Bcl-x. J. Biol. Chem.
283, 21315–21324.
Dassah, M., Patzek, S., Hunt, V.M., Medina, P.E., and Zahler, A.M. (2009). A
genetic screen for suppressors of a mutated 50 splice site identifies factors
associated with later steps of spliceosome assembly. Genetics 182, 725–734.
Dephoure, N., Zhou, C., Ville´n, J., Beausoleil, S.A., Bakalarski, C.E., Elledge,
S.J., and Gygi, S.P. (2008). A quantitative atlas of mitotic phosphorylation.
Proc. Natl. Acad. Sci. USA 105, 10762–10767.
Ditchfield, C., Keen, N., and Taylor, S.S. (2005). The Ipl1/Aurora kinase family:
methods of inhibition and functional analysis in mammalian cells. Methods
Mol. Biol. 296, 371–381.
Fesik, S.W. (2005). Promoting apoptosis as a strategy for cancer drug
discovery. Nat. Rev. Cancer 5, 876–885.Garneau, D., Revil, T., Fisette, J.F., and Chabot, B. (2005). Heterogeneous
nuclear ribonucleoprotein F/H proteins modulate the alternative splicing of
the apoptotic mediator Bcl-x. J. Biol. Chem. 280, 22641–22650.
Hardwick, J.M., and Youle, R.J. (2009). SnapShot: BCL-2 proteins. Cell 138,
404, 404.e1.
Harrington, E.A., Bebbington, D., Moore, J., Rasmussen, R.K., Ajose-Adeo-
gun, A.O., Nakayama, T., Graham, J.A., Demur, C., Hercend, T., Diu-Hercend,
A., et al. (2004). VX-680, a potent and selective small-molecule inhibitor of the
Aurora kinases, suppresses tumor growth in vivo. Nat. Med. 10, 262–267.
Karni, R., de Stanchina, E., Lowe, S.W., Sinha, R., Mu, D., and Krainer, A.R.
(2007). The gene encoding the splicing factor SF2/ASF is a proto-oncogene.
Nat. Struct. Mol. Biol. 14, 185–193.
Keene, J.D. (2007). RNA regulons: coordination of post-transcriptional events.
Nat. Rev. Genet. 8, 533–543.
Kromer, G. (1997). The proto-oncogene Bcl-2 and its role in regulation
apoptosis. Nat. Med. 3, 614–620.
Lapenna, S., and Giordano, A. (2009). Cell cycle kinases as therapeutic targets
for cancer. Nat. Rev. Drug Discov. 8, 547–566.
Letai, A.G. (2008). Diagnosing and exploiting cancer’s addiction to blocks in
apoptosis. Nat. Rev. Cancer 8, 121–132.
Li, X., and Manley, J.L. (2005). Inactivation of the SR protein splicing factor
ASF/SF2 results in genomic instability. Cell 122, 365–378.
Li, X., Wang, J., and Manley, J.L. (2005). Loss of splicing factor ASF/SF2
induces G2 cell cycle arrest and apoptosis, but inhibits internucleosomal
DNA fragmentation. Genes Dev. 19, 2705–2714.
Makarova, O.V., Makarov, E.M., Urlaub, H., Will, C.L., Gentzel, M., Wilm, M.,
and Lu¨hrmann, R. (2004). A subset of human 35S U5 proteins, including
Prp19, function prior to catalytic step 1 of splicing. EMBO J. 23, 2381–2391.
Massiello, A., and Chalfant, C.E. (2006). SRp30a (ASF/SF2) regulates the alter-
native splicing of caspase-9 pre-mRNA and is required for ceramide-respon-
siveness. J. Lipid Res. 47, 892–897.
Massiello, A., Roesser, J.R., and Chalfant, C.E. (2006). SAP155 Binds to ce-
ramide-responsive RNA cis-element 1 and regulates the alternative 50 splice
site selection of Bcl-x pre-mRNA. FASEB J. 20, 1680–1682.
Mercatante, D.R., Mohler, J.L., and Kole, R. (2002). Cellular response to an
antisense-mediated shift of Bcl-x pre-mRNA splicing and antineoplastic
agents. J. Biol. Chem. 277, 49374–49382.
Moore, M.J., and Silver, P.A. (2008). Global analysis of mRNA splicing. RNA
14, 197–203.
Orengo, J.P., Bundman, D., and Cooper, T.A. (2006). A bichromatic fluores-
cent reporter for cell-based screens of alternative splicing. Nucleic Acids
Res. 34, e148.
Pan, Q., Shai, O., Lee, L.J., Frey, B.J., and Blencowe, B.J. (2008). Deep
surveying of alternative splicing complexity in the human transcriptome by
high-throughput sequencing. Nat. Genet. 40, 1413–1415.
Paronetto, M.P., Achsel, T., Massiello, A., Chalfant, C.E., and Sette, C. (2007).
The RNA-binding protein Sam68 modulates the alternative splicing of Bcl-x. J.
Cell Biol. 176, 929–939.
Rines, D.R., Gomez-Ferreria, M.A., Zhou, Y., DeJesus, P., Grob, S., Batalov,
S., Labow, M., Huesken, D., Mickanin, C., Hall, J., et al. (2008). Whole genome
functional analysis identifies novel components required for mitotic spindle
integrity in human cells. Genome Biol. 9, R44.
Ross, D.T., Scherf, U., Eisen, M.B., Perou, C.M., Rees, C., Spellman, P., Iyer,
V., Jeffrey, S.S., Van de Rijn, M., Waltham, M., et al. (2000). Systematic varia-
tion in gene expression patterns in human cancer cell lines. Nat. Genet. 3, 227–
235.
Sanford, J.R., Wang, X., Mort, M., Vanduyn, N., Cooper, D.N., Mooney, S.D.,
Edenberg, H.J., and Liu, Y. (2009). Splicing factor SFRS1 recognizes
a functionally diverse landscape of RNA transcripts. Genome Res. 19,
381–394.
Schwerk, C., and Schulze-Osthoff, K. (2005). Regulation of apoptosis by alter-
native pre-mRNA splicing. Mol. Cell 19, 1–13.Cell 142, 625–636, August 20, 2010 ª2010 Elsevier Inc. 635
Shin, C., and Manley, J.L. (2002). The SR protein SRp38 represses splicing in
M phase cells. Cell 111, 407–417.
Stoilov, P., Lin, C.H., Damoiseaux, R., Nikolic, J., and Black, D.L. (2008).
A high-throughput screening strategy identifies cardiotonic steroids as alter-
native splicing modulators. Proc. Natl. Acad. Sci. USA 105, 11218–11223.
Taylor, J.K., Zhang, Q.Q., Wyatt, J.R., and Dean, N.M. (1999). Induction of
endogenous Bcl-xS through the control of Bcl-x pre-mRNA splicing by anti-
sense oligonucleotides. Nat. Biotechnol. 11, 1097–1100.
Wahl, M.C., Will, C.L., and Lu¨hrmann, R. (2009). The spliceosome: design prin-
ciples of a dynamic RNP machine. Cell 136, 701–718.636 Cell 142, 625–636, August 20, 2010 ª2010 Elsevier Inc.Wang, C., and Youle, R.J. (2009). The role of mitochondria in apoptosis. Annu.
Rev. Genet. 43, 95–118.
Warzecha, C.C., Sato, T.K., Nabet, B., Hogenesch, J.B., and Carstens, R.P.
(2009). ESRP1 and ESRP2 are epithelial cell-type-specific regulators of
FGFR2 splicing. Mol. Cell 33, 591–601.
Zhou, A., Ou, A.C., Cho, A., Benz, E.J., Jr., and Huang, S.C. (2008). Novel
splicing factor RBM25 modulates Bcl-x pre-mRNA 50 splice site selection.
Mol. Cell. Biol. 28, 5924–5936.
